Sign In

For Suspension of fresh subscription in certain schemes of NIMF, kindly refer to ADDENDUM

​​​​​​​​​​​​​​​​​​​​​​​ ​​​​​Home Products By Asset Class > ​ Equity Funds >  ​ Nippon India ​Pharma Fund.​ ​​​​​​​

Nippon India Pharma Fund

An open ended equity scheme investing in pharma sector

Product Label Close

This product is suitable for investors who are seeking*:

  • Long term capital growth.
  • investment predominantly in equity and equity related Securities of pharma & other associated companies.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them

Fund Riskometer

Nippon India Pharma Fund

Benchmark Riskometer

BSE Healthcare TRI

investMore investMore
  • Investment Objective:
    The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of pharma and other associated companies.

Fund PerformanceGrowth Plan - Growth Option

  • Latest NAV (08 Oct 2024)520.5451


NAV as on September 30, 2024: `522.8842

​Performance of Nippon India Pharma Fund as on 30/09/2024
Particulars1 Year CAGR %
3 Year CAGR %5 Year CAGR %Since Inception%
Nippon India Pharma Fund48.0519.3330.0621.48
B:BSE Healthcare TRI55.7120.0129.5716.63
AB:BSE Sensex TRI29.4813.9818.2616.65
Value of `10000 Invested
Nippon India Pharma Fund14,83616,99837,270522,885
B:BSE Healthcare TRI15,60917,29136,576228,392
AB:BSE Sensex TRI12,96614,81323,148229,154
Inception Date: Jun 5, 2004
B - Benchmark    |   AB - Additional Benchmark |   TRI - Total Return Index
Fund Manager: Sailesh Raj Bhan (Since Jun 2004)
As TRI data is not available since Since Inception of the scheme, benchmark performance is calculated using composite CAGR of BSE HC PRI values from date 04-Jun-2004 to date 23-Aug-2004 and TRI values since date 23-Aug-2004​

PERFORMANCE OF OTHER OPEN ENDED SCHEMES MANAGED BY FUND MANAGER: Sailesh Raj Bhan

Scheme Name/sCAGR %
1 Year Return 3 Years Return5 Years Return
Scheme Benchmark Scheme Benchmark Scheme Benchmark
Nippon India Multi Cap Fund45.4544.0628.1721.1426.7525.88
Nippon India Large Cap Fund38.8937.3622.1516.7622.1620.29

Note:

a.Mr. Sailesh Raj Bhan manages 3 open-ended schemes of Nippon India Mutual Fund.

b. In case the number of schemes managed by a fund manager is more than six, in the performance data of other schemes, the top 3 and bottom 3 schemes managed by fund manager has been provided herein.

c. Period for which schemes performance has been provided is computed basis last day of the month-end preceding the date of advertisement.

d. Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan).

TRI - Total Returns Index reflects the returns on the index arising from (a) constituent stock price movements and (b) dividend receipts from constituent index stocks, thereby showing a true picture of returns.

The performance of the equity scheme is benchmarked to the Total Return variant of the Index.

Mr. Sailesh Raj Bhan has been managing Nippon India Pharma Fund since Jun 2004, Nippon India Multi Cap Fund since Mar 2005, Nippon India Large Cap Fund since Aug 2007

Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investments. Returns for 1 year and above are compounded annualized(CAGR) and returns less than 1 year are simple annualized basis. 6 months simple annualized returns are provided for the schemes that are in existence for more than 6 months but have not completed 1 year.IDCW (if any) are assumed to be reinvested at the prevailing NAV. In case of Nippon India ETF Liquid BeES, returns are based on gross IDCW per unit declared by the Fund. Bonus (if any) declared has been adjusted.Face value of schemes is `10 per unit, except for the schemes as specified here. Face Value of Nippon India Liquid Fund, Nippon India Money Market Fund Nippon India Ultra Short Duration Fund, Nippon India Low Duration Fund and Nippon India ETF Liquid BeES is `1000 per unit. Face value of Nippon India ETF Junior BeES is `1.25 per unit. Face value of Nippon India Overnight Fund is `100 per unit. Face Value of Nippon India ETF Nifty BeES, Nippon India ETF Bank BeES, Nippon India ETF PSU Bank BeES, Nippon India ETF NV20, Nippon India ETF Hang Seng BeES, Nippon India ETF Gold BeES is `1 per unit. In case, the start/end date of the concerned period is non-business day, NAV of the previous date is considered for computation of returns. Performance details of closed ended and interval schemes are not provided since these are not comparable with other schemes. Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan).









​​

​​
Read more

Fund Details

  • Inception Date5 Jun 2004
  • Fund ManagerMr. Sailesh Raj Bhan
Current Investment Philosophy
    • The fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses.
    • The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.
Minimum Investment
5000.00

    and in multiples of Re. 1 thereafter

Fund Manager
Load Details

Entry Load*:

Not Applicable

*In terms of SEBI circular no. SEBI/IMD/CIR No.4/ 168230/09 dated June 30, 2009, no entry load will be charged by the Scheme to the investor effective August 1, 2009. Upfront commission shall be paid directly by the investor to the AMFI registered Distributors based on the investors' assessment of various factors including the service rendered by the distributor.

Exit Load**:

1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.

Nil, thereafter.

Exit load levied on the Units redeemed will be the rate prevailing at the time of the allotment of the Units. For Special products registrations, load for each transaction is based on the load structure applicable as on the registration date.

**If charged, the same shall be credited to the scheme immediately net of Goods & Service tax, if any.

Product label

This product is suitable for investors who are seeking*:

  • Long term capital growth.
  • investment predominantly in equity and equity related Securities of pharma & other associated companies.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them



Close

Portfolio

Select
​​

​​Related Downlo​​ads & Tools

Tools

  • SIP Calculator​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
  • Financial Calculator For SIP/SWP/STP
    ​​​​​​​​​​















How to Invest?

Contact our advisor to complete the process

Other Suggested Funds

Nippon India Banking & Financial Services Fund An open ended equity scheme investing in Banking & Financial Services Sector-Growth Plan - Growth Option

Latest NAV

575.2663 08-Oct-2024

Nippon India Power & Infra Fund An Open Ended Equity Scheme investing in power & infrastructure sectors-Growth Plan - Growth Option

Latest NAV

366.3768 08-Oct-2024

Nippon India Consumption Fund An Open Ended Equity Scheme following consumption theme.-Growth Plan - Growth Option

Latest NAV

211.5309 08-Oct-2024

Get the app